Using PARP Inhibitors in Advanced Ovarian Cancer.

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Using PARP Inhibitors in Advanced Ovarian Cancer.

Oncology (Williston Park, N.Y.) - 15 Jul 2018

O'Cearbhaill Roisin E

Abstract excerpt

Poly(ADP-ribose) polymerase (PARP) proteins are used by cells in several DNA repair processes. PARP inhibition can result in preferential death of cancer cells when another mechanism for repairing DNA is defective. Two PARP inhibitors, olaparib and rucaparib, have been approved by the US Food and Drug Administration (FDA) for the treatment of recurrent, BRCA-associated ovarian cancer. More recently, these two and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Exanthema
Share to Fatigue
Share to Indazoles
Share to Leukopenia

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Nausea

Share to Pneumonia

Share to Transaminases

Share to Vomiting

Source

Open in PubMed Open full text

Identifiers

PMID: 30080919
PMCID: PMC6662180

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.